Peptide PilotPeptide Pilot

mg ↔ units

Tesamorelin mg to units converter

Set your Tesamorelin vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

1.000

units

40.0

mL

0.400

Concentration: 2.50 mg/mL (assumes a U-100 insulin syringe).

Tesamorelin is a daily injection people use specifically to reduce stubborn deep belly fat (visceral adipose tissue). It's an analog of growth hormone-releasing hormone (GHRH) that prompts the pituitary to release more of the body's own GH. In FDA trials for HIV-related lipodystrophy, daily 2 mg injections reduced visceral fat by about 15–18% over 26 weeks. This page covers reconstitution math and daily dose logging.

How the Tesamorelin mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the Tesamorelin concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 2.5 mg/mL Tesamorelin solution, 1 mg comes out to 40 units, and 40 units comes out to 1 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 5 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for Tesamorelin

Tesamorelin is the complete 44-amino-acid sequence of human growth hormone-releasing hormone (GHRH), uniquely modified at its N-terminus with a trans-3-hexenoyl group. This single structural addition is designed to shield the peptide from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV), a key differentiator from other GHRH analogs. This protection results in a more sustained presence in plasma and a longer duration of action after administration. Consequently, its pharmacological profile and the protocols studied in literature differ significantly from shorter-lived compounds that target the same receptor.

Within the landscape of regulatory review, Tesamorelin holds a distinct position. It is the only GHRH analog that has secured and maintained FDA approval for a specific indication: the reduction of excess abdominal adiposity in HIV-infected individuals with lipodystrophy. This established history provides a substantial body of public data from clinical trials, delineating its parameters of use. The dose magnitudes documented in this research, often around 1 mg daily, are considerably larger than those for other peptides in its class, influencing everything from reconstitution strategy to administration technique.

Tesamorelin represents a significant modification of the endogenous growth hormone-releasing hormone (GHRH) peptide. It is a synthetic analog containing the full 44-amino-acid sequence of human GHRH, but with a crucial chemical addition. This addition, a trans-3-hexenoyl group attached to the N-terminus, is the defining structural feature of the molecule. Its purpose is to fortify the peptide against rapid enzymatic degradation, a primary limitation of administering native GHRH. This enhanced stability is central to how the peptide is studied and how its administration schedules are planned.

Tesamorelin mechanism in plain English

Tesamorelin functions by binding to and activating the growth hormone-releasing hormone receptor (GHRHR), located on somatotroph cells in the anterior pituitary gland. This is the identical pathway used by endogenous GHRH to stimulate the synthesis and pulsatile secretion of growth hormone. The critical distinction lies in its metabolic stability; while natural GHRH and unmodified analogs like sermorelin are quickly cleaved and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-IV), Tesamorelin's trans-3-hexenoyl modification sterically hinders this process. This resistance to breakdown extends its plasma half-life, allowing for prolonged GHRHR stimulation from a single dose.

The primary mechanism differentiating tesamorelin from native GHRH lies in its resistance to enzymatic breakdown. Endogenous GHRH is rapidly inactivated by the enzyme dipeptidyl peptidase IV (DPP-IV), which cleaves the peptide bond between the first two amino acids, Tyr1 and Ala2. Tesamorelin is engineered to prevent this. The trans-3-hexenoyl moiety, a six-carbon acyl group, is covalently bonded to the N-terminal tyrosine. This chemical shield sterically hinders the DPP-IV enzyme, physically blocking its access to the cleavage site. This protection results in a substantially longer plasma half-life, enabling the molecule to circulate and interact with GHRH receptors in the pituitary for an extended duration.

Tracking Tesamorelin unit counts

For a peptide administered daily at a relatively high volume, such as a 1 mg dose of Tesamorelin that may occupy 40 units, the single most valuable data point to log is the injection site location. Consistently administering a larger volume into the exact same subcutaneous tissue area day after day can lead to palpable lipohypertrophy, a localized hardening or swelling of adipose tissue that can impede absorption. Documenting and observing a systematic rotation schedule for administration sites (e.g., quadrant of the abdomen, left vs. right glute) is a key practice for anyone planning a long-term protocol, as it allows for the monitoring of tissue health and adherence.

Effective tracking of a tesamorelin protocol involves documenting more than just dose and time. Given its specific mechanism as a GHRH analog, logs can be enhanced by recording variables that provide context for its activity. This includes noting the timing of administration relative to food intake, as ghrelin, lipids, and glucose can influence the downstream GH-IGF-1 axis. Additionally, since local injection site reactions such as erythema or induration are sometimes noted in studies of GHRH analogs, it can be valuable to monitor and document the condition of the administration site. Tracking these details provides a more complete data set for later analysis of observed trends.

Common Tesamorelin conversion mistakes

  • Assuming the per-dose volume and syringe draw will be as small as sermorelin's and failing to plan for a larger subcutaneous injection.
  • Neglecting to systematically document and rotate injection sites, which can lead to localized lipohypertrophy that interrupts a planned daily schedule.
  • Mistaking the typical milligram (mg) dose for micrograms (mcg) in the calculator, leading to a thousand-fold dosing error.
  • Attempting to reconstitute a 5 mg vial with an excessively small diluent volume, making the large 1 mg dose difficult to measure and draw accurately.
  • Administering the daily dose in the evening by default, contrary to the morning administration schedule used in the vast majority of published clinical trials.
  • Mistaking the trans-3-hexenoyl modification for a simple carrier or delivery system, rather than the specific chemical shield it is.
  • Failing to distinctly log the molecule as tesamorelin, instead using the generic term 'GHRH', which obscures the critical stability difference in protocol review.
  • Neglecting to record whether the tracked material is the pharmaceutical product Egrifta or a research-grade compound, a distinction vital for data integrity.

Frequently asked questions about Tesamorelin mg ↔ units

Why is the Tesamorelin dose in milligrams (mg) when other GHRH analogs are often dosed in micrograms (mcg)?
Tesamorelin's milligram-level dosing is a function of its molecular structure and the extensive clinical research that established its use profile. As the full 44-amino-acid GHRH sequence, its molecular weight and receptor affinity necessitate a larger mass to achieve the desired level of pituitary stimulation. The protocols for its FDA-approved indication were developed around a 1 mg or 2 mg daily dose, reflecting its distinct pharmacology compared to smaller, truncated peptide fragments.
What specifically is the purpose of the trans-3-hexenoyl group on Tesamorelin?
The trans-3-hexenoyl group is a fatty acid-based modification chemically bonded to the start of the peptide chain. Its sole purpose is to serve as a physical shield, sterically hindering the enzyme DPP-IV from accessing its cleavage site on the GHRH sequence. This protection from enzymatic degradation is what grants Tesamorelin a significantly longer half-life compared to native GHRH, which is its primary design advantage.
Using a 5 mg vial reconstituted with 2 mL of water, how many units would a 1 mg dose be?
When a 5 mg vial is reconstituted with 2 mL of bacteriostatic water, the solution's final concentration is 2.5 mg/mL. To obtain a 1 mg dose from this solution, you would need to draw 0.40 mL. On any standard U-100 insulin syringe, a volume of 0.40 mL is equivalent to exactly 40 units.
Why is tracking injection site rotation especially important for Tesamorelin?
The emphasis on site rotation is a direct consequence of its common protocol: daily administration combined with a relatively large dose volume. Delivering a volume of 0.4 mL (40 units) or more into the same subcutaneous tissue spot every day increases the risk of lipohypertrophy, a benign but palpable thickening of fat tissue. This can alter absorption rates and impact comfort, making the careful logging and rotation of sites an important variable to monitor for consistent administration.
Can Tesamorelin be considered a longer-lasting version of sermorelin?
While both peptides activate the GHRH receptor, they are fundamentally different molecules. Sermorelin represents only the first 29 amino acids of the GHRH sequence. Tesamorelin is the full 44-amino-acid sequence and includes an additional protective modification. This structural difference gives Tesamorelin a much longer half-life and leads to different studied protocols with larger dose magnitudes.
Why was Tesamorelin studied with morning, rather than evening, administration?
The morning administration schedule seen in most clinical literature is tied to Tesamorelin's extended half-life. Because it resists rapid breakdown and provides a prolonged GHRH signal for many hours, it does not need to be timed to coincide with the body's primary nocturnal growth hormone pulse. A morning dose provides a sustained level of GHRH receptor stimulation throughout the day, a profile that was extensively studied and established for its approved indication.
What is the concrete chemical difference between tesamorelin and native GHRH?
Tesamorelin is the full 44-amino-acid sequence of human GHRH with one specific chemical modification. A trans-3-hexenoyl group is covalently attached to the N-terminal tyrosine residue. This addition serves to protect the molecule from rapid degradation by the DPP-IV enzyme, which is what gives tesamorelin a significantly longer half-life compared to unmodified, endogenous GHRH.
What is the difference between Tesamorelin and Egrifta for logging purposes?
The active molecule is identical; tesamorelin is the generic name for the peptide, and Egrifta is the brand name for the FDA-approved pharmaceutical product. The key difference for logging is the source and standardization. Egrifta comes in a fixed-dose kit with verified purity, while material labeled as 'tesamorelin' is typically for research purposes and may have different purity and handling considerations. It is critical to document which form is being studied for accurate record-keeping.
Why is the DPP-IV enzyme unable to cleave tesamorelin?
The DPP-IV enzyme is prevented from cleaving tesamorelin due to steric hindrance. The enzyme's active site must physically access the peptide bond between the first and second amino acids (Tyr1-Ala2) to break it. The bulky trans-3-hexenoyl group attached at the N-terminus acts as a physical shield, blocking the enzyme's approach. This structural defense preserves the full-length peptide, allowing it to remain active in plasma for much longer.

Related on Peptide Pilot

Save your Tesamorelin vial in the app

Download on the App Store
Get the App